Additive GABA modulation → excessive sedation
Additive CNS depression + additive hepatotoxicity
Additive liver stress
Kava has dopamine antagonist properties, may reduce levodopa effectiveness
Kava inhibits CYP2E1 (and other CYPs at high doses)
Additive CNS depression
Kava was banned in Germany, France, the UK, and other countries in 2002 after ~80 cases of hepatotoxicity, including some requiring liver transplant. Subsequent investigation found:
Our recommendation: Use only noble cultivar, root-only, water-extracted kava products from reputable manufacturers.
Not Prohibited
Reference identifiers on this page are being re-verified against PubMed. Some may not yet link to the paper named beside them.
, Pittler MH, Ernst E. Kava extract for treating anxiety. *Cochrane Database Syst Rev.* 2003.
(2003). PMID: 12535473
, Sarris J et al. Kava for generalised anxiety disorder: a 16-week double-blind, randomised, placebo-controlled trial.
, Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by Cimicifugae racemosae rhizoma: the isopropanolic extract is not the cause.
Independently graded against 173,636 indexed supplements with 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, and NIH DSLD | Last updated: April 2026
Not medical advice. Based on published clinical research and systematic reviews.